FY2025 · ended Dec 31, 2025 · Revenue $319,714, -96.0% YoY · Filed Mar 18, 2026
Vyome Holdings, Inc. (HIND) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $319,714 and a net loss of $10.3 million. As of Jun 30, 2026 it held $7.9 million in cash and investments and $17,310 in total debt.
Revenue (TTM)
$129,725
+103.8% vs year-ago TTM
Net income (TTM)
$-11.31M
-750.7% vs year-ago TTM
Operating cash flow (TTM)
$-5.58M
-342.0% vs year-ago TTM
Free cash flow
$-17.00M
+22.8% vs prior year
EPS
$-4.86
+99.9% vs prior year
Dividend per share
None
Shares outstanding
7.02M
-37.8% vs prior year
Net cash
$7.87M
as of Jun 30, 2026
Operating margin
-9190.1%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HIND (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Clemente, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1427570
- Former names
- ReShape Lifesciences Inc. (until Aug 14, 2025); OBALON THERAPEUTICS INC (until Jun 21, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $319,714 | $8.0M | $8.7M | $11.2M | $13.6M |
| Operating income | -$10.5M | -$1.0M | -$15.4M | -$46.4M | -$57.9M |
| Net income | -$10.3M | -$1.4M | -$11.4M | -$46.2M | -$63.1M |
| Diluted EPS | -$4.86 | -$6,001.39 | -$110.87 | -$108.90 | -$288.97 |
| Operating cash flow | -$3.7M | -$614,136 | -$17.0M | -$21.9M | -$15.4M |
| Free cash flow | — | — | -$17.0M | -$22.0M | — |
| Total assets | $6.5M | $1.4M | $10.7M | $11.1M | $52.5M |
| Total liabilities | $2.7M | $5.8M | $4.0M | $7.5M | $8.2M |
| Stockholders' equity | $3.8M | — | — | — | — |
| Cash and investments | $5.0M | $101,904 | $4.5M | $3.9M | $22.8M |
| Total debt | — | $156,000 | $262,000 | $171,000 | $279,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Aug 28, 2026 | Aug 25, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 25, 2026 | Aug 25, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
May 29, 2026 | May 28, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Apr 29, 2026 | Apr 24, 2026 |
All 693 Vyome Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.